L-Lysine Dosage: Why 500mg Once a Day Probably Isn't the Trial Dose
Educational summary — not medical advice. Lysine's cold-sore-prevention evidence is genuinely mixed even at the trial-matched dose; see the full evidence page before assuming this will work. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
The positive cold-sore-prevention trials used a sustained 1,000–3,000 mg/day, taken daily — not an occasional pill. McCune 1984 found a clean dose floor: 1,248 mg/day worked, but 624 mg/day did not. Griffith 1987, the strongest positive trial, used 3,000 mg/day for 6 months. Doses under ~1,000 mg/day, or as-needed dosing at the first tingle, don't match what any positive trial tested — and there's no established RDA or upper limit for supplemental lysine, only the trial range itself as a practical guide.
The dose gap: what's on the shelf vs. what the trials tested
Most single lysine tablets or capsules are 500–1,000 mg. Reaching the trial-relevant 1,000–3,000 mg/day means taking 1–3+ pills a day, every day, for months — not one pill, and not only when a sore starts. This is the single most common way lysine gets used incorrectly: as an as-needed remedy at the first tingle, rather than a sustained daily prophylactic. None of the positive trials tested as-needed dosing; all three (Griffith 1987, McCune 1984, Thein & Hurt 1984) dosed lysine every day for months, aiming to reduce the frequency and severity of future recurrences, not to shorten a sore already present.
| Question | Answer |
|---|---|
| How much? | 1,000–3,000 mg/day, sustained daily (the range across all three positive trials) |
| McCune 1984's dose floor? | 1,248 mg/day worked; 624 mg/day did not |
| Griffith 1987's dose (strongest positive result)? | 1,000 mg three times daily (3,000 mg/day) for 6 months |
| As-needed / at-first-tingle dosing? | Not what any positive trial tested — daily sustained use is the tested protocol |
| Is there an RDA or upper limit? | No — no confirmed deficiency disease or established ceiling for supplemental lysine |
| Does the label dose guarantee an effect? | No — Thein & Hurt tied benefit to serum level, not just the label dose (see below) |
Why the label dose alone doesn't tell the whole story
Thein & Hurt 1984 found something that helps explain why lysine's trial record is so inconsistent: the benefit tracked a specific serum lysine threshold (above roughly 165 nmol/ml), not simply whether someone was taking the labeled 1,000 mg/day. When serum lysine exceeded that threshold, recurrence dropped significantly; when it didn't, the label dose alone wasn't enough. That means two people taking the identical labeled dose may not reach the same blood level, depending on absorption, body size, and how much lysine they're already getting from food — a real, dose-and-absorption-dependent effect, not a simple on/off switch. It's also a likely part of why Milman 1980's null trial used the same 1,000 mg/day dose that showed some benefit elsewhere and still found "no effect on the recurrence rate" in its much larger sample (n=65).
Dose checker: are you actually hitting a trial-relevant dose?
Enter the L-lysine milligrams per serving from your label (look for "L-Lysine ___ mg" on the Supplement Facts panel — every product we track discloses this directly) and how many servings you take per day.
How to take it
- Target 1,000–3,000 mg/day, sustained daily, for months — not as-needed at the first tingle. That's what every positive trial actually tested.
- Don't stop at a sub-1,000 mg/day dose expecting the trial effect — McCune 1984's 624 mg/day arm showed no benefit while 1,248 mg/day did.
- Powder lets you titrate precisely to any gram amount, including doses between 1,000 mg tablet increments — see the cost comparison.
- Kidney disease? Talk to a clinician before high-dose amino acid supplementation.
- Active sore right now? Lysine won't treat it — antivirals (acyclovir, valacyclovir, docosanol) are the actual treatment; see how people actually use lysine for the prevention-vs-treatment distinction.
The trial-dose value pick
If you're dosing to match the trial range rather than guessing at a pill count, powder makes it easiest. Full ranking on best L-lysine.
Plain L-lysine powder, 1000 mg per gram scoop — measure directly to any trial-range dose.
As an Amazon Associate we earn from qualifying purchases. Ranked by verified cost at the trial-relevant dose, never commissions.
Frequently asked questions
How much lysine should I take per day for cold sores?
1,000-3,000 mg/day, sustained daily. McCune 1984: 1,248 mg/day worked, 624 mg/day did not. Griffith 1987's strongest positive result used 3,000 mg/day for 6 months. As-needed dosing doesn't match any positive trial.
Does the label dose guarantee an effect?
No — Thein & Hurt 1984 tied benefit to a serum lysine threshold (~165 nmol/ml), not just the label dose. Absorption varies between people, which helps explain inconsistent results across studies.
Is there an RDA or upper limit?
No official RDA or upper limit exists for supplemental lysine. The trial range (1,000-3,000 mg/day) plus the kidney-disease caution is the practical guide.
Is 3,000 mg/day safe?
Griffith 1987 used it for 6 months with no notable adverse-effect signal. General caution: kidney disease warrants clinician input before high-dose amino acid supplementation; mild GI upset is the most common side effect.
Related
- L-lysine: what it is & the honest evidence
- Best L-lysine — ranked by cost at the trial-relevant dose
- L-lysine for cold sores — how people actually use it
- Does lysine actually prevent cold sores? — the full trial reckoning
Sources
- Griffith RS, Walsh DE, Myrmel KH, et al.. "Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis." Dermatologica. 1987. PMID: 3115841 (3,000 mg/day dose basis).
- McCune MA, Perry HO, Muller SA, O'Fallon WM. "Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride." Cutis. 1984. PMID: 6435961 (1,248 mg/day vs. 624 mg/day dose-floor basis).
- Thein DJ, Hurt WC. "Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis." Oral Surg Oral Med Oral Pathol. 1984. PMID: 6438572 (serum-threshold finding).
- Milman N, Scheibel J, Jessen O. "Lysine prophylaxis in recurrent herpes simplex labialis: a double-blind, controlled crossover study." Acta Derm Venereol. 1980. PMID: 6153847
- Full product dataset: /lysine/cost-by-brand.json (CC BY 4.0).